IGlarLixi clinical trials
IGlarLixi is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 4. The sponsor with the most trials is Sanofi (1). The most-studied condition is Type 2 Diabetes (T2D).
Patient leaflets for IGlarLixi
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of IGlarLixi
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2D)
|
Phase 4 | Recruiting | Sanofi | China |
|
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Phase 4 | Recruiting | Shanghai Zhongshan Hospital | China |
|
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07274644 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
|
Phase 4 | Active, closed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with IGlarLixi
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sanofi | 1 |
| Shanghai Zhongshan Hospital | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about IGlarLixi trials
How many clinical trials are testing IGlarLixi?
3 current trials in our China register name IGlarLixi as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are IGlarLixi trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors IGlarLixi clinical trials?
Sanofi (1), Shanghai Zhongshan Hospital (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IGlarLixi works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IGlarLixi works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IGlarLixi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.